Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 43Active not recruiting 43Not yet recruiting 11Completed 4Terminated 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 8Carboplatin 7Pemetrexed 5Nivolumab 5Cyclophosphamide 5Cisplatin 5ixazomib 4durvalumab 4Specimen Handling 4Paclitaxel 4Bevacizumab 4ibrutinib 3fludarabine phosphate 3fludarabine 3Ipilimumab 3Gemcitabine 3Docetaxel 3Cetuximab 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2temsirolimus 2evolocumab 2enzalutamide 2daratumumab 2atezolizumab 2Trastuzumab 2Tomography, X-Ray Computed 2Standard of Care 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Dexamethasone × 30 days × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡